Worldwide experience with sugammadex sodium: Implications for the United States

AANA Journal

Volumn 83, Issue 2, 2015, Pages 107-114

  Welliver, Mark ^a   Cheek, Dennis ^a   Osterbrink, Juergen ^a   McDonough, John ^a  

^a NONE

Author keywords

Blocking agent; In vivo administration; Sugammadex

Indexed keywords

NEOSTIGMINE; SUGAMMADEX; ANDROSTANE DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; INHALATION ANESTHETIC AGENT; NEUROMUSCULAR BLOCKING AGENT; VECURONIUM;

ARTICLE; CLINICAL PRACTICE; ELECTROCONVULSIVE THERAPY; EXTUBATION; HEART DISEASE; HUMAN; INTUBATION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MALIGNANT HYPERTHERMIA; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; NEUROPHYSIOLOGICAL MONITORING; OBESITY; PARALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDERED BREATHING; UNITED STATES; AGONISTS; ANESTHESIOLOGY; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; INHALATION ANESTHESIA; PRACTICE GUIDELINE; PROCEDURES;

ANDROSTANOLS; ANESTHESIA, INHALATION; ANESTHESIOLOGY; ANESTHETICS, INHALATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; VECURONIUM BROMIDE;

EID: 84928881262     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Welliver M, McDonough J, Kalynych N, Redfern R. The discovery, development, and implications of sugammadex, a selective relaxant binding agent. Drug Design Dev Ther. 2009;2:49-59.
2. Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009(4):CD007362.
3. Staals LM, Snoeck MM, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010;104(1):31-39.
4. Hartmann J, Smeets JMW, de Zwart MAH, Peters SMA. In vitro dialysability of sugammadex (Org 25969), a selective relaxant binding agent for reversal of neuromuscular block induced by rocuronium [abstract A-555]. Eur J Anaesthesiol. 2006;23:144.
5. Cammu G, Van Vlem B, van den Heuvel M, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth. 2012;109(3):382-390.
6. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial. 2011;24(1):1-4.
7. Makar SH, Sawires HK, Farid TM, Ali WM, Schaalan MF. Effect of high-flux versus low-flux dialysis membranes on parathyroid hormone. Iranian J Kidney Dis. 2010;4(4):327-332.
8. Pompei L, Gigante A, Deflaviis A, Costa MG, Chiarandini P, Della Rocca G. Rocuronium and sugammadex administration in patients undergoing orthotopic liver transplantation [abstract 9AP4-8]. Eur J Anaesthesiol. 2012;29:142.
9. Cammu G, Coart D, De Graeve K, Beelen R. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study. Acta Anaesthesiol Belg. 2012;63(2):69-73.
10. deKam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. Int J Clin Pharmacol Ther. 2012;50(8):595-604.
11. Osaka Y, Shimada N, Satou M, Masuda T, Ando T, Kozono Y, Shimada M. A case of atrioventricular block (Wenckebach type) induced by sugammadex. J Anesth. 2012:26(4):627-628.
12. Konishi J, Suzuki T, Kondo Y, Baba M, Ogawa S. Rocuronium and sugammadex used effectively for electroconvulsive therapy in a patient with Brugada syndrome. J ECT. 2012;28(2):e21-e22.
13. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the Second Consensus Conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111(5):659-670.
14. Kogler J, Chalfe N, Karaman Ilić M, Hodoba N. Sugammadex reversal of rocuronium-induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine [abstract 9AP6-5]. Eur J Anaesthesiol. 2012;29:146.
15. Eisenkraft JB, Papatestas AE, Kahn CH, Mora CT, Fagerstrom R, Genkins G. Predicting the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology. 1986;65(1):79-82.
16. Challan Belval A, Tramoni G, Vedrinne JM, Olagne E, Vigneron M. The use of sugammadex in a patient with myasthenia gravis [French]. Ann Fr Anesth Reanim. 2012;31(6):569-570.
17. Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia. 2010;65(3):302-305.
18. Garcia V, Diemunsch P, Boet S. Use of rocuronium and sugammadex for caesarean delivery in a patient with myasthenia gravis. Int J Obstet Anesth. 2012;21(3):286-287.
19. Takeda A, Kawamura M, Hamaya I, Kitamura H, Muto R, Mitono H. A case of anesthesia for thoracoscopic thymectomy in a pediatric patient with myasthenia gravis: reversal of rocuronium-induced neuromuscular blockade with sugammadex [Japanese]. Masui. 2012;61(8):855-858.
20. Rudzka-Nowak A, Piechota M. Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex. Arch Med Sci. 2011;7(2):361-364.
21. Sungur Ulke Z, Yavru A, Camci E, Ozkan B, Toker A, Senturk M. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand. 2013;57(6):745-748.
22. de Boer H, van Esmond J, Booij LH, Driessen JJ. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy [case report]. Paediatr Anesth. 2009;19(12):1226-1228.
23. Stewart PA, Phillips S, de Boer HD. Sugammadex reversal of rocuronium-induced neuromuscular blockade in two types of neuromuscular disorders: myotonic dystrophy and spinal muscular atrophy [Spanish]. Rev Esp Anestesiol Reanim. http://www.sciencedirect.com/ science/article/pii/S0034935612003088. Accessed September 8, 2012.
24. Kashiwai A, Suzuki T, Ogawa S. Sensitivity to rocuronium-induced neuromuscular block and reversibility with sugammadex in a patient with myotonic dystrophy. Case Rep Anesthesiol. 2012(2012):107952.
25. Weekes G, Hayes N, Bowen M. Reversal of prolonged rocuronium neuromuscular blockade with sugammadex in an obstetric patient with transverse myelitis. Int J Obstet Anesth. 2010;19(3):333-336.
26. Kelsaka E, Karakaya D, Zengin EC. Use of sugammadex in a patient with amyotrophic lateral sclerosis. Med Princ Pract. 2012;22:304-306. http://content.karger.com/produktedb/produkte.asp?doi=343168. Accessed October 16, 2012.
27. Khan MH, Banerjee A. Anaesthesia and orphan disease: sugammadex in a patient with Huntington's disease undergoing thyroid lobectomy [letter]. Eur J Anaesthesiol. 2012;29(12):593-595.
28. Tirotta CF, Brandom B, Siddiqui MS, et al. Time course of rocuroniuminduced neuromuscular blockade in pediatric patients: a phase III, randomized, dose-response study. J Anesth Clin Res. 2012;3:189.
29. Eikermann M, Zaremba S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth. 2008;101(3):344-349.
30. Merck. Bridion prescribing information.
31. Forbes GB, Welle SL. Lean body mass in obesity. Int J Obes. 1983;7(2):99-107.
32. Hume R. Prediction of lean body mass from height and weight. J Clin Pathol. 1966;19(4):389-391.
33. Peeters PA, van den Heuvel MW, van Heumen E, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Invest. 2010;30(12):867-874.
34. Llauradó S, Sabaté A, Ferreres E, Camprubí I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012;117(1):93-98.
35. Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugam-madex in morbidly obese patients. Anaesthesia. 2011;66(8):721-775.